Shuttle Pharmaceuticals Holdings said it failed to meet Nasdaq’s filing requirement after missing the deadline for its quarterly report covering the fiscal period ended June 30, 2026.
The company, which operates a pharmaceutical software platform for molecular discovery and early-stage drug development, disclosed the lapse under Nasdaq Listing Rule 5250(c)(1), which mandates timely submission of Form 10-Q filings. Shuttle Pharmaceuticals stated it intends to file the overdue report "as soon as practicable" and plans to submit a compliance plan to Nasdaq outlining corrective steps.
If accepted, Nasdaq may grant an exception allowing up to 180 calendar days from the original filing deadline to restore compliance. The company warned, however, that there is "no assurance" the plan will be accepted or that compliance will be achieved within the extended period.
The non-compliance notice will be published on Nasdaq’s market data network and distributed to third-party data providers starting around September 4, 2026. While the company’s common stock will continue trading without immediate disruption, failure to meet the revised deadline risks delisting.
Shuttle Pharmaceuticals also operates United Dogecoin, a digital infrastructure subsidiary focused on blockchain, artificial intelligence, and high-performance computing workloads. The filing delay does not affect the subsidiary’s operations, which remain separate from the company’s pharmaceutical software business.
